Skip to main content

Manning Paul B

In the past year, 2 open-market purchase filings worth $20.5M and 1 sale filing worth $12.8M.

Current role at each company

Open-market trades in the past year

Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.

Bought
$20.5M
2 filings
Sold
$12.8M
1 filing
Net
+$7.71M
Bought minus sold
Companies
3
With open-market trades

Trades

Every Form 4 that lists Manning Paul B as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.

LQDA Liquidia Corp

Director5 trades

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jun 8, 2026 (view filing)Jun 44 daysManning Paul BDirectorSSale−200.0K$63.91−$12.8M−20.0%798.3K after5 lots
Sep 2, 2025 (view filing)Aug 28-Sep 25 daysManning Paul BDirectorSSale−670.8K$28.26−$19.0M−60.9%430.8K after4 lots
Sep 16, 2024 (view filing)Sep 124 daysManning Paul BDirectorPPurchase+337.1K$8.90+$3.00M+70.3%816.3K after
Dec 18, 2023 (view filing)Dec 144 daysManning Paul BDirectorPPurchase+279.3K$7.16+$2.00MNew position279.3K after
Apr 19, 2022 (view filing)Apr 181 dayManning Paul BDirectorPPurchase+392.2K$5.10+$2.00MNew position392.2K after

CADL Candel Therapeutics, Inc.

Director4 trades

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Feb 26, 2026 (view filing)Feb 233 daysLateManning Paul BDirectorPPurchase+550.5K$5.45+$3.00M+24.9%2.76M after
Dec 18, 2024 (view filing)Dec 162 daysManning Paul BDirectorPPurchase+1.25M$6.00+$7.50M+2,325.5%1.30M after2 lots
Aug 4, 2021 (view filing)Jul 296 daysManning Paul BDirector, 10% OwnerPPurchase+1.63M$8.00+$13.0M+2,901.8%1.68M afterAmended
Jul 29, 2021 (view filing)Jul 27-292 daysManning Paul BDirectorPPurchase+56.0K$7.34+$411.0KNew position56.0K after2 lots

VRCA Verrica Pharmaceuticals Inc.

Director, 10% Owner11 trades

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Nov 25, 2025 (view filing)Nov 25Same dayManning Paul BDirector, 10% OwnerPPurchase+1.38M$4.24+$5.83M+53.3%3.96M after
Nov 25, 2025 (view filing)Nov 25Same dayManning Paul BDirector, 10% OwnerPPurchase+2.75M$4.24+$11.7M+460.3%3.35M after
Nov 25, 2025 (view filing)Nov 25Same dayManning Paul BDirector, 10% OwnerPPurchase+343.8K–––343.8K afterDerivative
Nov 25, 2025 (view filing)Nov 25Same dayManning Paul BDirector, 10% OwnerPPurchase+687.7K–––687.7K afterDerivative
Nov 26, 2024 (view filing)Nov 224 daysManning Paul BDirector, 10% OwnerPPurchase+18.4M––+234.7%26.3M after
Nov 26, 2024 (view filing)Nov 224 daysManning Paul BDirector, 10% OwnerPPurchase+4.49M––+303.3%5.98M after
Nov 26, 2024 (view filing)Nov 224 daysManning Paul BDirector, 10% OwnerPPurchase+18.4M–––9.21M afterDerivative2 lots
Nov 26, 2024 (view filing)Nov 224 daysManning Paul BDirector, 10% OwnerPPurchase+4.49M–––2.25M afterDerivative2 lots
Jul 24, 2023 (view filing)Jul 24Same dayManning Paul BDirector, 10% OwnerPPurchase+200.0K$5.02+$1.00M+2.6%7.85M after
Jul 5, 2022 (view filing)Jul 5Same dayManning Paul BDirector, 10% OwnerPPurchase+4.76M$2.10+$10.0M+53.6%13.7M after

See all 11 trades at VRCA

TSHA Taysha Gene Therapies, Inc.

10% Owner9 trades

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jun 3, 2025 (view filing)May 304 daysManning Paul B10% OwnerPPurchase+750.0K$2.75+$2.06M+35.9%2.84M after
Jul 1, 2024 (view filing)Jun 274 daysManning Paul B10% OwnerPPurchase+1.33M$2.25+$3.00MNew position1.33M after
Nov 20, 2023 (view filing)Nov 173 daysManning Paul B10% OwnerPPurchase+100.0K$1.63+$163.0K+0.6%16.6M after
Aug 16, 2023 (view filing)Aug 16Same dayManning Paul B10% OwnerPPurchase+16.5M$0.90+$14.8MNew position16.5M after
Nov 2, 2022 (view filing)Oct 312 daysManning Paul BDirector, 10% OwnerPPurchase+1.50M$2.00+$3.00M+1,054.8%1.64M after
Feb 4, 2022 (view filing)Feb 2-32 daysManning Paul BDirector, 10% OwnerPPurchase+108.0K$7.80+$842.7K+315.8%142.2K after2 lots
Feb 4, 2022 (view filing)Feb 2-32 daysManning Paul BDirector, 10% OwnerPPurchase+93.6K$7.79+$729.1K+4.7%2.09M after3 lots
Nov 29, 2021 (view filing)Nov 245 daysManning Paul BDirector, 10% OwnerPPurchase+2.20K$13.19+$29.0K+6.9%34.2K after
Nov 24, 2021 (view filing)Nov 231 dayManning Paul BDirector, 10% OwnerPPurchase+20.0K$12.54+$250.8K+166.7%32.0K after

ABOS Acumen Pharmaceuticals, Inc.

10% Owner1 trade

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jul 8, 2021 (view filing)Jul 62 daysManning Paul B10% OwnerPPurchase+312.5K$16.00+$5.00M+10.3%3.35M afterDuplicate filing